NCT00722735 (FLUT) is a Phase 2 clinical trial of Finafloxacin in Urinary Tract Infections, sponsored by MerLion Pharmaceuticals GmbH.

Who is sponsoring NCT00722735?

NCT00722735 is sponsored by MerLion Pharmaceuticals GmbH.

What drugs are being tested in NCT00722735?

Interventions in NCT00722735: Finafloxacin, Ciprofloxacin.

What condition does NCT00722735 study?

NCT00722735 studies Urinary Tract Infections.

Is NCT00722735 still recruiting?

NCT00722735 is currently completed. Last updated 10 June 2009.

Last reviewed 2009-06-10 · How we verify

NCT00722735: FLUT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Double-Blind, Double-Dummy, Prospective, Randomized Multiple-Site Study of Oral Finafloxacin 300 mg b.i.d. Versus Oral Ciprofloxacin 250 mg b.i.d. in Patients With Lower Uncomplicated UTI (uUTI) With a Treatment Duration of 3 Days

Completed Phase 2 Last updated 10 June 2009

What this trial tests

Phase 2 trial testing Finafloxacin in Urinary Tract Infections in 36 participants. Completed in 1 April 2009.

Timeline

1 October 2008

Primary endpoint
1 April 2009

1 April 2009

Quick facts

Lead sponsor	MerLion Pharmaceuticals GmbH
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	36
Start date	1 October 2008
Primary completion	1 April 2009
Estimated completion	1 April 2009
Sites	2 locations across Germany, Singapore

Drugs / interventions tested

Finafloxacin (FINAFLOXACIN) — full drug profile →
Ciprofloxacin (Ciprofloxacin) — full drug profile →

Conditions studied

Urinary Tract Infections — all drugs for Urinary Tract Infections →

Sponsor

MerLion Pharmaceuticals GmbH — full company profile →

Who can join

Adults 18 to 55, female only, with Urinary Tract Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Bacteriological eradication of the initial pathogen.
Time frame: 4-6 days

Sponsor's own description

To compare the bacteriological eradication rates of Finafloxacin and Ciprofloxacin in female patients with uUTI.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.
Ma YX, Wang CY, Li YY, Li J, et al · · 2020 · cited 170× · PMID 31921562 · DOI 10.1002/advs.201901872
Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates.
Vente A, Bentley C, Lückermann M, Tambyah P, et al · · 2018 · cited 12× · PMID 29339393 · DOI 10.1128/aac.02325-17
Antibacterials with Novel Chemical Scaffolds in Clinical Development.
Heimann D, Kohnhäuser D, Kohnhäuser AJ, Brönstrup M. · · 2025 · cited 10× · PMID 39847315 · DOI 10.1007/s40265-024-02137-x

Verify or expand the search:

Other recruiting trials for Urinary Tract Infections

Currently open trials in the same condition.

NCT06976125 — Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulat · NA · recruiting
NCT06808451 — Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture · NA · recruiting
NCT07186465 — Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis · Phase 4 · recruiting
NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers · Phase 1 · recruiting
NCT06715306 — Intravenous Versus Oral Treatment of the Main Acute Infections · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00722735 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MerLion Pharmaceuticals GmbH
Last refreshed: 10 June 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00722735.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing